cemiplimab
sanofi,regeneron
['cemiplimab']
a phase 2, multicenter study showed that four doses of neoadjuvant cemiplimab (anti pd-1 antibody) led to a pathological complete response in 51% of patients with locally advanced cutaneous squamous-cell carcinoma. #esmo22 
The New England Journal of Medicine (https://t.co/YGfDrRsIhE) is the world’s leading medical journal and website.